Profectus Biosciences

Contact: Jeffrey Meshulam  
Location: Baltimore, MD  
Email: meshulam@profectusbiosciences.com  
Tel: 443-743-1107  
Website: www.profectusbiosciences.com

Company Profile

Industry Sector: Biotechnology, Prophylactic & Therapeutic Vaccines

Company Overview: Profectus BioSciences, Inc. is a clinical-stage biotechnology company pioneering a major evolutionary step in the design and development of preventive and therapeutic vaccines. Our approach is based on the flexible Prime/Boost System of Vaccination (PBS Vax™) that provides the ability to "tune" the immune response for a specific target and disease context.

Target Market(s): The company develops vaccines for markets with significant commercial potential as well as those intended for emergency use or to have a significant global health impact. This opportunity is a therapeutic vaccine for HSV-2 infection.

Management

Leadership: A seasoned vaccine development team with members from big pharma, whose expertise covers all aspects of vaccine development with proven skills necessary to create new vaccines that will have a significant impact for patients worldwide.

Jeffrey Meshulam, President
John Eldridge, Ph.D., Chief Scientific Officer

Product Pipeline

Assuming capital is raised by Q3 2016

<table>
<thead>
<tr>
<th>Milestone</th>
<th>Cost (M)</th>
<th>2016</th>
<th>2017</th>
<th>2018</th>
<th>2019</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Build vaccine, Complete preclinical animal studies</td>
<td>$1.4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cGMP Manufacture, release PBS Vax™ HSV-2, Complete Preclinical Safety</td>
<td>$7.5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>File IND, Execute Phase I Clinical Trial</td>
<td>$1.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exit with potential upside $60M through acquisitions of product by large pharma/biotech interest